Retrospective study on the effect of Astragalus preparations on serum thyrotropin receptor antibody level in patients with Graves’ disease

DAI Zhengqian; SHEN Zhibi; ZHOU Zhenhua; CHEN Dongping; ZHANG Liqiong; YAO Di

doi:10.16305/j.1007-1334.2020.01.013

您当前的位置：

首页 >

文章列表页 >

Retrospective study on the effect of Astragalus preparations on serum thyrotropin receptor antibody level in patients with Graves’ disease

更新时间：2022-08-31

- Retrospective study on the effect of Astragalus preparations on serum thyrotropin receptor antibody level in patients with Graves’ disease
- Shanghai Journal of Traditional Chinese Medicine Vol. 54, Issue 1, Pages: 52-55(2020)
- 作者机构：
  
  1. 上海中医药大学附属曙光医院医务一处,上海,200021
  2. 上海中医药大学附属曙光医院肾病科,上海,200021
  3. 上海中医药大学附属曙光医院内分泌科,上海,200021
  4. 上海中医药大学附属曙光医院信息科,上海,200021
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2020.01.013
  CLC：
扫描看全文
DAI Zhengqian, SHEN Zhibi, ZHOU Zhenhua, et al. Retrospective study on the effect of Astragalus preparations on serum thyrotropin receptor antibody level in patients with Graves’ disease. [J]. Shanghai Journal of Traditional Chinese Medicine 54(1):52-55(2020)
DOI：

DAI Zhengqian, SHEN Zhibi, ZHOU Zhenhua, et al. Retrospective study on the effect of Astragalus preparations on serum thyrotropin receptor antibody level in patients with Graves’ disease. [J]. Shanghai Journal of Traditional Chinese Medicine 54(1):52-55(2020) DOI： 10.16305/j.1007-1334.2020.01.013.

摘要

目的：观察黄芪类制剂对格雷夫斯病患者血清促甲状腺素受体抗体(TRAb)水平的影响。方法：收集上海中医药大学附属曙光医院2016年8月至2018年7月格雷夫斯病初诊患者173例,按照用药情况分为对照组(117例)、治疗组(56例),对照组采用甲巯咪唑治疗,治疗组在对照组治疗措施的基础上,加用黄芪类制剂(黄芪胶囊、灵芪参口服液或含有黄芪饮片的中药复方),疗程至少6个月。比较两组血清TRAb、游离甲状腺素(FT,4,)、促甲状腺激素(TSH)水平的变化情况。结果：①=3\*GB3重复测量资料的方差分析结果显示,TRAb、TSH和FT,4,的组内变异中的时间因素存在显著统计学意义(P,<,0.05)；TRAb、TSH的时间×组别因素存在显著统计学意义(P,<,0.05),FT,4,的时间×组别因素不存在显著统计学意义(P,>,0.05)。TSH的组间变异中的组别因素存在显著统计学意义(P,<,0.05),TRAb、FT,4,组间变异中的组别因素不存在显著统计学意义(P,>,0.05)。②治疗1个月与治疗前组内比较,治疗组血清TRAb、TSH、FT,4,水平差异有统计学意义(P,<,0.05),对照组血清TSH、FT,4,水平差异有统计学意义(P,<,0.05)；治疗2个月、治疗3个月、治疗6个月与治疗前组内比较,两组血清TRAb、TSH、FT,4,水平差异均有统计学意义(P,<,0.05)。③=2\*GB3组间治疗2个月、治疗3个月比较,血清TRAb水平差异有统计学意义(P,<,0.05)；组间治疗6个月比较,血清TRAb、TSH、FT,4,水平差异有统计学意义(P,<,0.05)。结论：随着治疗时间的延长,相对于单纯使用甲硫咪唑,加用黄芪类制剂能更好地改善格雷夫斯病患者的甲状腺功能,降低血清TRAb水平。

Abstract

Objective:To observe the effect of Astragalus preparation on thyrotropin receptor antibody (TRAb) of patients with Graves’ disease. MethodsCollect 173 cases of patients with Graves’ disease from August 2016 to July 2018 and divide them into the control group (117 cases) and the treatment group (56 cases) according to the treatment used. Both groups were treated with methimazole and the treatment group was also given Astragalus preparations (Astragalus capsule, lingqishen oral liquid or TCM decoction containing Astragalus) for 6 months at least. The changes of serum TRAb,free thyroxine (FT,4,) and thyroid stimulating hormone (TSH) were compared between the two groups. Results:①=3\*GB3The results of ANOVA showed that there was significant statistical significance in the time factor of intragroup variation of TRAb, TSH and FT4 (P,<,0.05); there was significant statistical significance in the time × group factor of TRAb and TSH (P,<,0.05); there was no significant statistical significance in the time × group factor of FT4 (P,>,0.05). There was significant statistical significance in the group factors of TSH (P,<,0.05), but not in TRAb and FT4 (P,>,0.05). ②The differences of serum TRAb, TSH and FT,4, levels in the treatment group were statistically cant beforesignifi and after one-month-treatment (P,<,0.05) and the differences of serum TSH and FT,4, levels in the control group were also significant before and after one-month-treatment (P,<,0.05); The differences of serum TRAb, TSH and FT,4, level in both groups were significant before and after two-month-treatment, three-month-treatment and six-month-treatment respectively (P,<,0.05). ③The differences of serum TRAb level between two groups were statistically significant (P,<,0.05) when compared after 2-month treatment and after 3-month-treatment; there were significant differences (P,<,0.05) in the level of serum TRAb, TSH and FT,4, between two groups after six-month treatment. Conclusion:With the prolongation of treatment time, compared with the use of methimazole alone, Astragalus preparations can better improve the thyroid function and reduce the serum TRAb level in patients with Graves’ disease.

关键词

格雷夫斯病黄芪甲巯咪唑促甲状腺素受体抗体甲状腺功能免疫

Keywords

Graves’ diseaseHuangqi (Astragalus membranaceus)methimazolethyrotropin receptor antibody (TRAb)thyroid functionimmunity

references

Views

166

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Discussion on prevention and treatment of COVID-19 with traditional Chinese medicine from immunoregulation

Clinical study on Jianpi Wenshen Ruanjian Jiedu formula, Kang’ai injection and low-dose chemotherapy in the treatment of advanced non-small cell lung cancer of spleen kidney deficiency type in the elderly

Effects of Yiqi Fusheng Recipe combined with chemotherapy on tumor growth and tumor infiltrating lymphocytes in tumor-bearing mice with gastric cancer

Effects of Astragalus Angelica Mixture combined with tacrolimus on immune and renal functions in patients with refractory nephrotic syndrome

Pharmacological mechanism of anti-inflammatory and immunomodulatory effects of alkaloids from Peganum harmala:Research advances

Related Author

No data

Related Institution

School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine

Key Laboratory of Health Identification and Assessment of Shanghai/Laboratory of Traditional Chinese Medicine Four Diagnostic Information

National Traditional Chinese Medicine Clinical Research Base,Oncology Department, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Oncology Department, Shanghai Chest Hospital

Department of Oncology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

⁰